Diabetes as a consequence of COVID-19

A research team involving the Cluster of Excellence PMI has shown that the SARS-CoV-2 coronavirus can also damage the pancreas


The SARS-CoV-2 coronavirus, which causes the coronavirus disease COVID-19, can penetrate many different body cells. This has been shown in multiple research papers published in recent weeks. Thus, not only can the function of the respiratory tract and the lungs be severely disrupted, but also numerous other organs. The SARS-CoV-2 virus can also penetrate the so-called beta cells in the pancreas and damage them, as a research team involving the Cluster of Excellence “Precision Medicine in Chronic Inflammation” has now observed for the first time. These cells are responsible for producing the insulin required for a healthy metabolism. A SARS-CoV-2 infection can apparently disrupt this function, which as a result leads to diabetes. The observations were published today (September 2nd, 2020) by Professor Matthias Laudes, Schleswig-Holstein Excellence-Chair for endocrinology, diabetology and clinical nutritional medicine at Kiel University and his research team of the Clinic of Internal Medicine I at the University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, together with researchers from Munich and Dresden, in the renowned scientific journal Nature Metabolism.

The publication is an initial description of insulin deficiency diabetes after a COVID-19 illness, based on an observed case. “A 19-year-old patient came to us in the clinic with newly-developed severe diabetes with insulin deficiency. It could be shown that he apparently had experienced a SARS-CoV-2 infection a few weeks before,” reported Laudes, who is also a member at the steering committee of the Cluster of Excellence “Precision Medicine in Chronic Inflammation” (PMI). “Such an insulin deficiency diabetes, i.e. type 1 diabetes, is usually triggered by an autoimmune response, in which the immune system incorrectly identifies the beta cells in the pancreas as foreign and attacks them. But this autoimmune response was not present in this patient. We assume that here, the SARS-CoV-2 virus itself attacked the beta cells,” continued Laudes. This also fits with the fact that the beta cells possess a crucial receptor: the ACE2 receptor. The SARS-CoV-2 virus can specifically bind with this receptor. The receptor is also used by the virus as an entry point into the other body cells which it attacks.

The lead author of the publication is the medical doctor and early career researcher Dr. Tim Hollstein, who only joined the department of Professor Laudes at the beginning of this year, after a research stay at the National Institute of Health (NIH) in the USA. “I am delighted that Dr. Hollstein could make such an important observation as a young early career researcher. This newly-discovered metabolic disease demonstrates how important a detailed clinical and laboratory chemical characterization of COVID-19 can be for patients at a university endocrinological center,” said Laudes.

Under the leadership of cluster spokesperson Professor Stefan Schreiber, the UKSH is also conducting a long-term follow-up study into COVID-19 patients under the name “COVIDOM”, in which all persons reported as infected in Schleswig-Holstein will be invited to participate. “This success of Professor Laudes and his team underlines the importance of accurate follow-up observation after COVID-19.  We are certain that as a result of this disease, even more health-relevant metabolic problems can arise,” said PMI spokesperson Professor Stefan Schreiber, head of “COVIDOM” and director at the Department of Internal Medicine I at the UKSH, Campus Kiel.


Prof. Dr. med. Matthias Laudes
Schleswig-Holstein Excellence-Chair
Head of Endocrinology, Diabetology and Clinical Nutritional Medicine
Department of Internal Medicine I, UKSH, Campus Kiel
 +49 431/500-22217

Contact person for COVIDOM:

Prof. Dr. med. Stefan Schreiber
Director at the Department of Internal Medicine I, UKSH, Campus Kiel
+49 431/500-22200

portrait photo
© SoulPicture

Professor Matthias Laudes is a member of the Steering Committee of the PMI Excellence Cluster, Schleswig-Holstein Excellence-Chair and head of the Department of Endocrinology, Diabetology and Clinical Nutritional Medicine at the Clinic for Internal Medicine I at the UKSH, Campus Kiel.

portrait photo
© privat

Dr. Tim Hollstein, first author of the study, conducts research at the Christian-Albrechts-University of Kiel and works as an assistant physician of the Clinic for Internal Medicine I of the UKSH, Campus Kiel.

Original publication

Tim Hollstein* Dominik M. Schulte*, Juliane Schulz, Andreas Glück, Anette G. Ziegler, Ezio Bonifacio, Mareike Wendorff, Andre Franke, Stefan Schreiber, Stefan R. Bornstein und Matthias Laudes: Autoantibody-negative Insulin-dependent Diabetes Mellitus after SARS-CoV-2 infection: a case report. Nat Metab (2020). DOI: 10.1038/s42255-020-00281-8
*these autors contributes equally


Frederike Buhse
Public Relations, Cluster of Excellence PMI
+49 431/880 4682


University Medical Center Schleswig-Holstein
Staff Unit Integrated Communication
Oliver Grieve, press spokesman
+49 431/500-10700


About the Cluster of Excellence PMI

The Cluster of Excellence "Precision Medicine in Chronic Inflammation" (PMI) is being funded from 2019 to 2025 through the German Excellence Strategy (ExStra). It succeeds the "Inflammation at Interfaces” Cluster, which was already funded in two periods of the Excellence Initiative (2007-2018). Around 300 members from eight institutions at four locations are involved: Kiel (Kiel University, University Medical Center Schleswig-Holstein (UKSH), Muthesius University of Fine Arts and Design, Kiel Institute for the World Economy (IfW), Leibniz Institute for Science and Mathematics Education (IPN)), Lübeck (University of Lübeck, University Medical Center Schleswig-Holstein (UKSH)), Plön (Max Planck Institute for Evolutionary Biology) and Borstel (Research Center Borstel - Leibniz Lung Center).

The goal is to translate interdisciplinary research findings on chronic inflammatory diseases of barrier organs to healthcare more intensively, as well as to fulfil previously unsatisfied needs of the patients. Three points are important in the context of successful treatment, and are therefore at the heart of PMI research: the early detection of chronic inflammatory diseases, the prediction of disease progression and complications, and the prediction of individual responses to treatment.

Press office

Frederike Buhse
Public Relations, Excellence Cluster PMI

Cluster of Excellence "Precision Medicine in Chronic Inflammation"
Scientific Office
Head: Dr. habil. Susanne Holstein Postal
Christian-Albrechts-Platz 4, 24118 Kiel, Germany
Contact: Sonja Petermann
 +49 (0)431 880-4850, fax: +49 (0)431 880-4894
Twitter: PMI @medinflame